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============

The discovery of the novel coronavirus (nCoV), later named SARS-CoV-2, dates back to December 2019 when multiple cases of atypical pneumonia emerged in Wuhan, China \[[@CR1]\]. Although initially thought to be a variant of coronavirus with moderate communicability, the virus resulted in an upsurge in mortality, especially among seniors with co-morbid conditions \[[@CR2]\]. Within a matter of weeks the outbreak from Wuhan spread to all corners of the world and was labeled as a pandemic with millions of confirmed cases and hundreds of thousands of deaths \[[@CR3]\]. With this growing menace, it is prudent to pinpoint the specific factors leading to adverse outcomes and the opportunities to explore from these challenges. A plethora of half-truths and low-grade evidence is emerging every day, confusing treating physicians. One example is the treatment of patients with hypertension with angiotensin converting enzyme (ACE) inhibitors (ACEi) or angiotensin receptor blockers (ARBs), with opinions on their use ranging from harm to no harm to providing benefits with regard to COVID-19.

ACEs convert angiotensin-I to its various activated forms including angiotensin-II and angiotensin 1--9, all leading to vasoconstrictive effects (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR4]\]. SARS-CoV-2 also acts through similar receptors to enter cells where the virus preferentially replicates in respiratory epithelia \[[@CR5]\]. There are two schools of thought regarding the role of cellular ACE2 receptors. In one, the continuous use of ACEi and ARBs increases the expression of ACE2 on cellular surfaces, which, once exposed to SAR-CoV-2, increases viral intracellular entry, thus enhancing viral replication \[[@CR6]\]. In the other, ACE functional blockers block cellular entry of SARS-CoV-2 and thus improve patient outcomes \[[@CR7]\]. The detailed mechanism of action of ACE and angiotensin are shown in Fig. [1](#Fig1){ref-type="fig"}. The existing literature also suggests that raised ACE and angiotensin-II levels are not good prognostic indicators \[[@CR8]\]. This short review will attempt to address and consolidate the prevailing evidence about the use of ARBs and ACEi in subjects with COVID-19.Fig. 1Schematic showing the mechanism of action of angiotensin with angiotensin converting enzymes (ACE) and further downstream pathways, together with the interaction of SARS-CoV-2 with the receptor. *ACEi*ACE inhibitor, *ARB* angiotensin receptor blocker, *AT*x*R* angiotensin receptor type-*x*, MAS G-protein coupled receptor

Review methodology {#Sec2}
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Search engines used for the study included Google Scholar and PubMed. Key search words included "COVID-19 and use of ACE inhibitors or ARBs", along with filters including last 1 year, humans and English language. This yielded 307 articles initially (last searched 11 May 2020), which were further shortlisted as per the content. The major shortlisting criteria included specific use of ARBs or ACEi in COVID-19. Data previous to December 2019 were excluded as COVID-19 was non-existent prior to this date. The data search was later expanded to include "SARS corona and use of ACE inhibitors or ARBs". We ended up with 17 related studies, as shown in Table [1](#Tab1){ref-type="table"}, that specifically addressed our question.Table 1Available evidence regarding the potential effects of angiotensin receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACEi) in patients with SARS-CoV-1 (SARS) or SARS-CoV-2 infection (COVID-19)Study conclusionsUse recommended?Evidence gradeReferencesACEi/ARBs reduce IL-6 and increase CD3 and CD8, thus reducing COVID-19 severity; ACEi and ARBs are beneficial to use in COVID-19YesAMeng et al. \[[@CR10]\]Animal model: mice infection with SARS-CoV leading to lung injury attenuated by RAS blockade (SARS-CoV-1)YesBImai et al. \[[@CR11]\]Advantage gain by denying SARS-CoV-2 assess to ACE2 receptor may compromise its vasoconstrictive, fibrotic and renal function effects (ACE2 has protective role in acute lung injury)NoCPerico et al. \[[@CR12]\]RAS inhibition, though increases ACE2 expression, will still reduce hazards in SARS-CoV-2 infection and fulminant myocarditisYesCHanff et al. \[[@CR13]\]Past ACEi treatment, but not ARBs, cause expression of ACE2; data are conflicting and more research is neededNoCVaduganathan et al. \[[@CR14]\]ACEi/ARBs can be continued during COVID-19YesCTalreja et al. \[[@CR15]\]Supported use of ARBs and ACEi in COVID-19 patients with underlying pneumonia and hypertensionYesDSun et al. \[[@CR7]\]AT1R blockers, including ARBs, can help reduce COVID-19 morbidity and mortalityYesDGurwitz \[[@CR16]\]Use of ACEi and/or ARBs can have increased risk of severe COVID-19NoDDiaz \[[@CR6]\]More animal models and randomized controlled trials are needed to confirm the potential utility of ACE recombinant ACE2 proteinPossibleDBatlle et al. \[[@CR17]\]Medications increasing ACE2 activity may be useful for SARS-CoV-2 infectionYesDCheng et al. \[[@CR18]\]RAS blockade by ACE2 up-regulation can result in cardiac benefits and possibly achieve desirable outcomes in COVID-19PossibleDSouth et al. \[[@CR19]\]Animal data: increasing ACE2 expression can help protect against pulmonary and cardiovascular  hazards; recommend continuing use of ACEi and ARBs to manage hypertension in COVID-19 patientsYesDDanser et al. \[[@CR5]\]Insufficient evidence that ACEi or ARBs cause more harm in COVID-19 but more research is warrantedInsufficient dataDPatel and Verma \[[@CR20]\]ACEi/ARBs increase ACE2 receptor expression; this increase is utilized by SARS-CoV-2 to result in severe diseaseNoDZheng et al. \[[@CR21]\]ACEi/ARBs can increase ACE2 causing higher viral loads, but can be protective against lung injury and cardiac damage; ACEi/ARB treatments should not be discontinuedPossibleDGuo et al. \[[@CR22]\]Mixed effect on lung and cardiac tissue with ACE2 regulation; no definitive opinion for using ACEi/ARBs for hypertensive patients with COVID-19Insufficient dataDRico-Mesa et al. \[[@CR23]\]*AT1R* angiotensin 2 receptor type 1, *RAS* renin angiotensin system, *ACE* angiotensin converting enzyme

All included studies were evaluated for the study endpoints and the evidence was graded for quality using GRADE (Grading of Recommendations Assessment, Development and Evaluation) \[[@CR9]\]. The evidence was graded as follows:Grade A: Evidence usually derived from high quality randomized controlled trials from multiple centers.Grade B: Evidence is derived from one high quality study with minimal study limitations. This research warrants further high quality trials to approve.Grade C: Evidence is derived from few studies with limitations, such as case--control studies with small sample sizes, and needs further high quality research work for approval.Grade D: Poor quality research originating from some expert opinion with no conduct of direct research work.

Results {#Sec3}
=======

There was an understandable paucity of trials and quality evidence. We studied the data related to the two highly pathogenic coronaviruses---SARS-CoV-1 (SARS) and SARS-CoV-2 (COVID-19)---that have presented in the last two decades. Table [1](#Tab1){ref-type="table"} shows the data, supporting or otherwise, regarding the use of ACEi and ARBs in patients with SARS-CoV-1 or -2 infection.

Discussion {#Sec4}
==========

ACEi and ARBs are primarily used for the long-term treatment of hypertension and associated left ventricular dysfunction. In theory, it seems that the mechanistic effect of these drugs in causing ACE2 receptor up-regulation could allow SARS-CoV-2 to find more targets to attack and infect, thus worsening the patient's condition. Conversely, avoiding the use of ACEi and ARBs in patients with hypertension could cause result in worsening of hypertension control and accelerated adverse cardiovascular effects. The data in Table [1](#Tab1){ref-type="table"} highlight the weaknesses in the available evidence with only one controlled trial and few studies recommending ACEi/ARB use in patients with COVID-19 \[[@CR7], [@CR16]--[@CR19]\]. The results of the animal model study by Imai et al. suggest that administering ACEi reverses induced lung damage, suggesting that ARBs and ACEi may have utility in COVID-19 cases involving similar lung damage \[[@CR11]\]. The recent position statements by the European Society of Cardiology and American Heart Association suggest continuing current treatment with ARBs and ACEi in hypertensive patients with COVID-19 \[[@CR24], [@CR25]\]. However, in our opinion, further research in COVID-19 animal models or RCTs is much needed to clarify the mechanistic details of ACE2 interactions with SARS-Cov-2 and medications and their combined interactions. Although medical science can never provide complete answers to the many questions raised, the way forward for further research needs to delineated. From this discussion and data review, it seems increased ACE2 expression is beneficial to avoid lung injury and possibly cardiotoxicity; thus it may be useful in avoiding complications in non-hypertensive subjects with COVID-19 \[[@CR11], [@CR12]\]. Furthermore, due to the shortcomings of the currently available data, differences in individual statements and position statements, and the repeated call or caution, results from well-designed trials are required to avoid any degree of ambiguity in short-term and possible long-term side effects \[[@CR19], [@CR20], [@CR22], [@CR23]\].

Recommendations {#Sec5}
===============

To conclude, we suggest the following recommendations for using ACEi and ARBs in patients with COVID-19:The use of ARBs in particular and ACEi may be continued in hypertensive patients with COVID-19 (evidence grade: D).The use of ARBs or ACEi to manage COVID-19 in non-hypertensive patients is not recommended (evidence grade: D).More quality trials are needed to study the beneficial and harmful effects of ACEi and ARB use in hypertensive patients infected with COVID-19 (evidence grade: C).

SHK: concept, database search, manuscript writing. SKZ: database search, COVID-19 details coverage, manuscript writing.
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